Anthem and Boehringer Ingelheim Initiate Largest Pragmatic Clinical Trial in World

Anthem (ANTM) shares drifted marginally lower after the companty said the first patients were enrolled in Airwise, a pragmatic clinical trial in chronic obstructive pulmonary disease (COPD) to study how commonly prescribed medicines may reduce the occurrence of exacerbations of COPD.

The research is a collaboration between Anthem, its research subsidiary, HealthCore, Inc. and Boehringer Ingelheim, a company with a long history of leadership in respiratory research worldwide, according to a statement.

The trial will further enhance the understanding of the role of long-acting muscarinic antagonists, long-acting beta-agonists and inhaled corticosteroids in reducing the risk of COPD exacerbations.

Anthem shares traded near the top end of their 52-week price range of $114.85 – $198.98.

Leave a Comment